Denali Capital files updated investor presentation for proposed merger with Longevity Biomedical

Semnur Pharmaceuticals, Inc.

Exhibit 99.1 is an August 2023 investor presentation for the business combination with Longevity Biomedical, superseding the January 2023 version.
The presentation will be used in meetings with investors; no specific new deal terms or financial projections are disclosed in the filing.
Upon closing, each of Denali and Longevity will become wholly-owned subsidiaries of Holdco, renamed Longevity Biomedical, Inc.
The transaction remains subject to regulatory and stockholder approvals; the registration statement was filed on March 29, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.